February 11, 2009
Prezista 75mg available for HIV
The approval for pediatric use was based on results from DELPHI, a 24-week, open-label, Phase 2 trial, in which antiretroviral treatment-experienced HIV-1 infected pediatric patients received Prezista co-administered with ritonavir in combination with other antiretroviral agents. At week 24, 74% of patients had a decrease from baseline in plasma HIV-1 RNA viral load. The proportion of pediatric patients reaching undetectable viral load was 50%.
Prezista is already approved for the treatment of HIV infection in adult patients in 300mg, 400mg, and 600mg dosage strengths.
For more information call (877) REACH-TT or visit www.prezista.com.